Latent Epstein-Barr VirUs

• Inhibits EBNA1 protein expression, a key EBV component linked to autoimmune conditions like multiple sclerosis and lupus

• Suppresses p-STAT3 signaling, helping immune cells better detect and eliminate EBV-infected cells

• Activates cellular self-destruct pathways (p53, XAF1, GADD45a) that target compromised cells harboring latent virus

• Shows up to 10x stronger cytotoxic effects against EBV-infected B cells compared to healthy cells

• Rapidly suppresses key EBV transformation proteins EBNA1, EBNA2, and LMP1 that drive autoimmune dysfunction

• Targets viral mechanisms involved in multiple sclerosis, lupus, and Hashimoto's thyroiditis

• Reduces EBV viral load by 30% inside infected cells and 55% in surrounding medium through RNA synthesis disruption

• Silences key EBV genes (EBNA1, EBNA2, EBNA3A, LMP2A) that help the virus remain hidden and replicate

• Strengthens cellular defenses by modifying immune receptors, making it harder for EBV to spread between cells

• EGCG from matcha directly blocks EBV protein LMP1, preventing viral reactivation from latent to active phases

• Clinical studies show 50-75% reduction in EBV viral copies within infected cells through targeted gene suppression

• Addresses chronic fatigue symptoms associated with EBV reactivation and mitochondrial dysfunction

• Suppresses LMP1 viral gene expression, preventing EBV from transforming healthy B cells into abnormal, cancer-like cells

• Blocks key survival pathways (NF-κB and STAT-3) that EBV uses to help infected cells resist immune system elimination

• Reduces production of IL-6 and IL-10 cytokines that support infected cell survival and immune system evasion